Sputnik V COVID-19 vaccine

Вакцина Спутник V (cropped)

COVID-19 vaccination center in Gostiny Dvor 17

Fábrica do DF produz vacina Sputnik V (50874030898)

Посещение пункта вакцинации от COVID-19 (С. Собянин; декабрь 2020) (3)

SputnikVEfficacy001

Совещание с членами Правительства (В. Путин; 11 августа 2020) – (01)

Sputnik V COVID-19 vaccine

The Sputnik V COVID-19 vaccine (Russian: Спутник V) is a COVID-19 vaccine developed by the Gamaleya Research Institute of Epidemiology and Microbiology in Russia. It is an adenovirus viral vector vaccine, which means it uses a modified virus to deliver genetic material from the SARS-CoV-2 virus into human cells to stimulate an immune response.

Development and Approval

The development of Sputnik V began in early 2020, shortly after the World Health Organization declared the COVID-19 outbreak a pandemic. The vaccine was named after the Sputnik 1 satellite, the first artificial satellite launched by the Soviet Union in 1957. The vaccine was registered by the Russian Ministry of Health on August 11, 2020, making it the first COVID-19 vaccine to be approved for use in any country.

Mechanism of Action

Sputnik V uses two different adenoviruses (rAd26 and rAd5) for the first and second doses, respectively. This heterologous prime-boost vaccination strategy is designed to enhance the immune response. The adenoviruses are engineered to carry the gene for the SARS-CoV-2 spike protein, which prompts the body to produce an immune response against the virus.

Efficacy and Safety

Clinical trials have shown that Sputnik V has an efficacy rate of approximately 91.6%. The vaccine has been shown to be effective in preventing symptomatic COVID-19 and severe cases of the disease. Common side effects include mild flu-like symptoms, pain at the injection site, and fatigue.

Distribution and Use

Sputnik V has been approved for emergency use in over 70 countries worldwide. It is distributed in two doses, administered 21 days apart. The vaccine can be stored at temperatures between 2-8 degrees Celsius, making it easier to distribute compared to some other COVID-19 vaccines that require ultra-cold storage.

Controversies and Criticisms

The early approval of Sputnik V raised concerns among some scientists and public health experts due to the lack of published data from large-scale clinical trials at the time of its registration. However, subsequent peer-reviewed studies have supported its efficacy and safety.

Related Pages

• COVID-19 pandemic
• COVID-19 vaccine
• Gamaleya Research Institute of Epidemiology and Microbiology
• Adenovirus
• SARS-CoV-2
• World Health Organization

See Also

• Pfizer–BioNTech COVID-19 vaccine
• Moderna COVID-19 vaccine
• AstraZeneca COVID-19 vaccine
• Johnson & Johnson COVID-19 vaccine